We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques.
- Authors
Li, Hongzhao; Hai, Yan; Lim, So-Yon; Toledo, Nikki; Crecente-Campo, Jose; Schalk, Dane; Li, Lin; Omange, Robert W.; Dacoba, Tamara G.; Liu, Lewis R.; Kashem, Mohammad Abul; Wan, Yanmin; Liang, Binhua; Li, Qingsheng; Rakasz, Eva; Schultz-Darken, Nancy; Alonso, Maria J.; Plummer, Francis A.; Whitney, James B.; Luo, Ma
- Abstract
HIV mutates rapidly and infects CD4+ T cells, especially when they are activated. A vaccine targeting conserved, essential viral elements while limiting CD4+ T cell activation could be effective. Learning from natural immunity observed in a group of highly HIV-1 exposed seronegative Kenyan female sex workers, we are testing a novel candidate HIV vaccine targeting the 12 viral protease cleavage sites (PCSs) (the PCS vaccine), in comparison with a vaccine targeting full-length Gag and Env (the Gag/Env vaccine) in a Mauritian cynomolgus macaque/SIV model. In this study we evaluated these vaccines for induction of mucosal antibodies to SIV immunogens at the female genital tract. Bio-Plex and Western blot analyses of cervicovaginal lavage samples showed that both the PCS and Gag/Env vaccines can elicit mucosal IgG antibody responses to SIV immunogens. Significantly higher increase of anti-PCS antibodies was induced by the PCS vaccine than by the Gag/Env vaccine (p<0.0001). The effect of the mucosal antibody responses in protection from repeated low dose pathogenic SIVmac251 challenges is being evaluated.
- Subjects
IMMUNOGLOBULINS; PROTEOLYTIC enzymes; T cells; IMMUNITY; SEROLOGY
- Publication
PLoS ONE, 2018, Vol 13, Issue 8, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0202997